Weight & Metabolic
Do GLP-1s Affect Bone Density?
The short answer
The published meta-analyses disagree with each other. A 25-study pooled analysis in people with type 2 diabetes found GLP-1 receptor agonists were linked to improved hip and spine bone density and no increased fracture risk. A separate 7-study meta-analysis of the same drug class found no significant change in bone density at all — but a significant rise in a marker of bone breakdown. A Danish trial found liraglutide alone lost more hip and spine density than exercise alone, despite similar weight loss. Almost none of this evidence comes from people taking these drugs for obesity without diabetes, and almost none of it comes from older adults, where the stakes are highest.
Quick answers
- What is it?
- Whether GLP-1 medications like semaglutide and tirzepatide affect bone mineral density.
- Why are people interested in it?
- People losing significant weight on these drugs want to know if their bones are at risk.
- What has actually been studied?
- Two meta-analyses of randomized trials (25 studies and 7 studies) in people with type 2 diabetes, a Danish randomized trial comparing exercise, liraglutide, and both combined, and a 20-person pilot trial in older adults.
- How strong is the evidence?
- Systematic review evidence, but the two major meta-analyses on the same drug class directly disagree with each other, and almost none of the evidence comes from people taking these drugs for obesity without diabetes or from older adults.
- What don't we know yet?
- Whether obesity-dose GLP-1 therapy without diabetes affects bone differently, what explains the contradiction between the two meta-analyses, and how older adults or people with osteoporosis are affected.
- Where can I read the original research?
- Sources at the bottom of this page: Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis and Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta-Analysis.
The short answer: The published meta-analyses on this question do not agree with each other. One pooled analysis of 25 studies in people with type 2 diabetes found GLP-1 receptor agonists were associated with improved bone mineral density at the hip and spine and no increased fracture risk. A separate meta-analysis of 7 randomized trials found no significant change in bone density anywhere — but a significant rise in a blood marker of bone breakdown. A Danish trial found liraglutide alone lost more hip bone than exercise alone despite equivalent weight loss. And a small pilot trial in older adults found essentially nothing happened to their bones either way. This is a genuinely unsettled question, and most of what's been measured wasn't measured in the population asking it.
What the research shows
Meta-analysis one: bone density went up
A 2025 systematic review and meta-analysis pooled 25 randomized controlled trials of GLP-1 receptor agonists in people with type 2 diabetes, tracking bone mineral density (BMD) and bone turnover markers. The headline findings: lumbar spine BMD improved (mean difference 0.07 g/cm², 95% CI 0.06 to 0.09), hip neck BMD improved (0.05 g/cm², CI 0.03 to 0.08), and total hip BMD improved (0.06 g/cm², CI 0.04 to 0.07), all compared with control groups. Markers of bone formation — P1NP, osteocalcin, bone-specific alkaline phosphatase, vitamin D — also moved in a favorable direction, while a resorption marker (β-CTX) dropped. Fracture risk itself was not significantly different between groups (relative risk 0.80, 95% CI 0.47 to 1.36).
Meta-analysis two: bone density didn't move, and a resorption marker rose
A separate 2024 meta-analysis restricted itself to 7 randomized trials meeting stricter inclusion criteria — human studies, at least 4 weeks of treatment, a placebo or untreated comparator, and reported bone outcomes. It found no significant change in BMD at the femoral neck, total hip, or lumbar spine. But CTX — the same resorption marker that fell in the first analysis — rose in this one (mean difference 0.04 μg/L, 95% CI 0.01 to 0.07). Bone formation markers were unchanged. The two meta-analyses drew on overlapping but not identical sets of trials, used different inclusion criteria, and arrived at opposite conclusions about the direction bone resorption was moving.
What happens when weight loss is added into the picture
A Danish randomized trial gives one of the more direct comparisons available. Adults with obesity first went through an 8-week low-calorie diet, then were randomized to a year of exercise, liraglutide 3.0 mg, both combined, or placebo. All active groups lost more weight than placebo (7.0 kg with placebo up to 16.9 kg with the combination). Bone density in the combination group was statistically unchanged from placebo at the hip and spine. But liraglutide alone lost significantly more bone than exercise alone, at both the hip (mean difference −0.013 g/cm², P=.03) and spine (−0.016 g/cm², P=.04) — despite comparable weight loss between those two groups. The trial's authors read this as evidence that mechanical loading from exercise, not the drug, is what protected bone during weight loss.
The one older-adult trial that exists
Given that older adults are the population where bone loss carries the most immediate risk, the evidence here is strikingly thin. A 2025 pilot trial randomized 20 adults with an average age of 72.7 to semaglutide plus lifestyle counseling or lifestyle counseling alone for 20 weeks. The drug group lost significantly more weight (−5.3% vs. −0.89%, P<0.01). Despite that, there was no significant difference in whole-body BMD (P=.77) or bone turnover markers between groups. The authors were careful to flag this as a small, short pilot and not a basis for conclusions — but it's also nearly the entire dedicated evidence base in this specific population.
The state of the broader literature
A 2025 critical appraisal summarizing this space concluded that GLP-1 receptor agonists show a "neutral or negative, albeit not clinically significant" effect on bone turnover markers and BMD in human studies, while preclinical (animal) data suggested a more positive picture. Fracture risk specifically does not appear elevated in the studies available so far, at clinically used doses. A 2023 narrative review reached a similar conclusion from a different angle: most human studies were conducted in people with diabetes, used doses set for glycemic control rather than obesity, did not set bone health as a primary endpoint, and ran for a matter of months rather than years.
What we don't know yet
Whether obesity-dose GLP-1 therapy, without diabetes, affects bone differently. Nearly all of the meta-analyzed trials enrolled people with type 2 diabetes. Semaglutide and tirzepatide are now used at higher, obesity-specific doses in people without diabetes, and that population has not been separately studied for bone outcomes at scale.
What actually explains the contradiction between the two meta-analyses. Different trial sets, different inclusion criteria, and different statistical approaches produced opposite directional findings on the same drug class. Neither review could run a combined meta-analysis that resolved this.
Whether fracture risk changes over the long term. The longest fracture data available spans roughly two years. Bone remodeling is slow; a two-year window may not be long enough to detect risk that would show up after five or ten years of use.
How older adults and people with existing osteoporosis are affected. The one dedicated pilot trial enrolled 20 people for 20 weeks. Larger, longer trials specifically in this population do not yet exist.
Whether resistance training or protein/calcium supplementation changes the outcome. The Danish trial hints that exercise protects bone independent of the drug, but this hasn't been tested as a structured intervention alongside GLP-1 therapy in a trial built to answer that question.
Sources
- Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetologica, 2025;62(5):589–606. DOI
- Kim HJ, Choi SA, Gu MS, et al. Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta-Analysis. Diabetes/Metabolism Research and Reviews, 2024;40(6):e3843. DOI
- Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open, 2024;7(6):e2416775. DOI
- Dinkla L, Beavers KM, Robbins R, et al. Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trial analysis. Frontiers in Aging, 2025;6:1691007. DOI
- Anastasilakis AD, Paccou J, Palermo A, Polyzos SA. The effects of anti-obesity medications on bone metabolism: A critical appraisal. Diabetes, Obesity & Metabolism, 2025;27(9):4674–4688. DOI
- Herrou J, Mabilleau G, Lecerf JM, et al. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity. Calcified Tissue International, 2023;114(2):86–97. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Weight & Metabolism | Evidence Index: semaglutide · liraglutide · tirzepatide
Sources
- Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis
- Acta Diabetologica, 2025 · n=25 · DOI
- Effects of Glucagon-Like Peptide-1 Receptor Agonist on Bone Mineral Density and Bone Turnover Markers: A Meta-Analysis
- Diabetes/Metabolism Research and Reviews, 2024 · n=7 · DOI
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment
- JAMA Network Open, 2024 · n=195 · DOI
- Bone mineral density and turnover response to GLP-1 receptor agonists in older adults: a 20-week pilot trial
- Frontiers in Aging, 2025 · n=20 · DOI
- The effects of anti-obesity medications on bone metabolism: A critical appraisal
- Diabetes, Obesity & Metabolism, 2025 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.